Takeda Pharmaceutical’s Q1 FY2026 financial results show revenue of \u00a51.2199 trillion (YoY +10.2%) and operating profit of \u00a5201.4 billion (\u25b33.1%), with net income of \u00a5113.3 billion (\u25b38.9%). Attention is needed on future performance trends.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4502","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-07-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4502-20260730-01.pdf","jir_short_summary":"Takeda Pharmaceutical's Q1 FY2026 financial results show revenue of \u00a51.2199 trillion (YoY +10.2%) and operating profit of \u00a5201.4 billion (\u25b33.1%), with net income of \u00a5113.3 billion (\u25b38.9%). Attention is needed on future performance trends.","jir_summary":"### Performance Overview\nTakeda Pharmaceutical's Q1 FY2026 showed strong revenue of \u00a51.2199 trillion (+10.2%), while operating profit and net income declined compared to the same period last year. Revenue growth was driven by exchange rate factors and contributions from new products, with sales expansion in key segments such as gastrointestinal disorders and oncology. Core indicators remained solid, but increased R&D and SG&A expenses put pressure on profits.\n\n### Outlook and Impact on Shareholders\nThe full-year forecast for FY2026 projects revenue of \u00a54.64 trillion (+3%), but profits face continued challenges from rising costs and R&D investments. The dividend forecast remains at \u00a5102, with ongoing shareholder returns. The company\u2019s strategy emphasizes new drug development and overseas expansion to achieve long-term growth. Investors should monitor exchange rate fluctuations and the progress of new drug launches.","jir_financial_highlights":"Revenue: \u00a51.2199 trillion (YoY +10.2%)\nOperating Profit: \u00a5201.4 billion (Compared to the same period last year \u25b33.1%)\nNet Income: \u00a5113.3 billion (Compared to the same period last year \u25b38.9%)\nNet income attributable to owners of the parent: \u00a5113.2 billion (Compared to the same period last year \u25b38.9%)\nEarnings per Share (EPS): \u00a571.65 (Compared to the same period last year \u25b38.9%)","jir_category":"","jir_hashtags":"#TakedaPharmaceutical, #FinancialResults, #JapaneseStocks","jir_key_figures":"Revenue: \u00a51.2199 trillion (YoY +10.2%)\nOperating Profit: \u00a5201.4 billion (\u25b33.1%)\nNet Income: \u00a5113.3 billion (\u25b38.9%)","jir_meta_title":"[Takeda Pharmaceutical] Q1 FY2026 Financial Results | Revenue of \u00a51.2199 trillion (+10.2%)","jir_meta_description":"Takeda Pharmaceutical's Q1 FY2026 financial results show revenue of \u00a51.2199 trillion (+10.2% YoY) with decreased profits but demonstrating steady business development. Attention is on future outlook.","jir_og_title":"[Takeda Pharmaceutical] Q1 FY2026 Financial Results | Revenue of \u00a51.2199 trillion (+10.2%)","jir_og_description":"Takeda Pharmaceutical\u2019s Q1 FY2026 showed strong revenue but decreased profits. Focus is on future business strategy and shareholder returns amid the earnings report.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6852,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-90542","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n